PAG
VKTX icon

Private Advisor Group’s Viking Therapeutics VKTX Stock Holding History

Private Advisor Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Buy
8,383
+132
+2% +$4.26K ﹤0.01% 2059
2026
Q1 		$268K Buy
8,251
+749
+10% +$24.1K ﹤0.01% 2265
2025
Q4 		$264K Sell
7,502
-732
-9% -$25.9K ﹤0.01% 2243
2025
Q3 		$216K Buy
8,234
+234
+3% +$6.98K ﹤0.01% 2289
2025
Q2 		$212K Buy
+8,000
New +$211K ﹤0.01% 2198
2025
Q1 		– Sell
-6,526
Closed -$263K – 2420
2024
Q4 		$263K Sell
6,526
-2,560
-28% -$146K ﹤0.01% 1936
2024
Q3 		$575K Buy
9,086
+3,625
+66% +$213K ﹤0.01% 1543
2024
Q2 		$289K Buy
5,461
+958
+21% +$62.8K ﹤0.01% 1907
2024
Q1 		$369K Buy
+4,503
New +$200K ﹤0.01% 1707
2020
Q3 		– Sell
-4,450
Closed -$32K – 3364
2020
Q2 		$32K Buy
+4,450
New +$29.5K ﹤0.01% 2326

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Private Advisor Group's VKTX Position: Q2 2026 in Review

Private Advisor Group increased its Viking Therapeutics (VKTX) stake by 1.6% in Q2 2026, buying an estimated $4.26K and bringing the position to 8,383 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Private Advisor Group first reported a position in VKTX in Q2 2020 and has held it in 10 quarters since. The position peaked at $575K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Private Advisor Group held 8,383 shares of Viking Therapeutics worth $327K as of Q2 2026.
  • Private Advisor Group bought 132 Viking Therapeutics shares in Q2 2026, an estimated $4.26K.
  • Viking Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2059 holding.
  • Private Advisor Group first reported a position in Viking Therapeutics in Q2 2020 and has held it in 10 quarters since.
  • Private Advisor Group's Viking Therapeutics position peaked at $575K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.